Clinical trials: Transition Cell Cancer, open to volunteers
Solid Tumor, MET Alteration
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
- Trial name
- NCT06669117
- Testing
- VERT-002
- Where
- 19 sites in United States, Belgium and 7 more
- Volunteers
- 140 people
- Sponsor
- Pierre Fabre Medicament
Hematopoietic Cell Transplant
The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant.
- Trial name
- MedMemos (NCT07718204)
- Testing
- MedMemos
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nationwide Children's Hospital
Congenital Melanocytic Nevi, Melanoma, Skin
Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN.
- Conditions
- Congenital Melanocytic Nevi, Melanoma, Skin, Nevi and Melanomas
- Trial name
- NevustoMel (NCT06605417)
- Testing
- Methylomics, RNA sequencing, Spatial transcriptomics
- Where
- 2 sites in France, Spain
- Volunteers
- 100 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Chronic Pancreatitis, Pancreatic Cancer
Immune Repertoire Decoding for Chronic Pancreatitis-to-Pancreatic Cancer Risk Stratification
This study will follow people with chronic pancreatitis, people with pancreatic cancer, and healthy volunteers. The goal is to better understand why some people with chronic pancreatitis may later develop pancreatic cancer.
- Trial name
- NCT07612566
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Burns, Acute Pain
VR-PAT During Home Burn Dressings - Multisite
This study will evaluate the effectiveness of smartphone Virtual Reality Pain Alleviation Therapy (VR-PAT) as a pain distraction tool during repeated at-home burn dressing changes among 100 children (age 6-17 years) with a burn…
- Conditions
- Burns, Acute Pain, Procedural Pain, Injuries
- Trial name
- NCT05673551
- Testing
- VR-PAT
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Nationwide Children's Hospital
Transition Cell Cancer
Is the Normal Looking Bladder Mucosa on WL Cystoscopy During TURBT Really Normal and Can NBI Detect Hidden Tumor
As every urologist does transurethral resection of bladder tumor. So there are instances in which the operating surgeon is not sure whether the normal-looking mucosa or the inflammatory changes are really benign or if we are…
- Trial name
- NCT06729346
- Where
- 2 sites in Pakistan
- Volunteers
- 100 people
- Sponsor
- Armed Forces Institute of Urology, Rawalpindi
Non-Small Cell Lung Cancer, Solid Tumor
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for…
- Trial name
- NCT05940116
- Testing
- HS-20117
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Hansoh BioMedical R&D Company
Non-Squamous Non-Small Cell Lung Cancer
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in…
- Trial name
- NCT06417008
- Testing
- HS-20117, Aumolertinib
- Where
- 2 sites in China
- Volunteers
- 1,080 people
- Sponsor
- Hansoh BioMedical R&D Company